ALEXANDRA BEWLEY: Open Payments
NPI 1851772958 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$366 in 16 payments from 9 companies in 2025. Trend: 2023 $480 · 2024 $939 · 2025 $366
Food & beverage: $366
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| Grifols USA, LLC | 2 | $54 |
| PFIZER INC. | 1 | $30 |
| GENZYME CORPORATION | 1 | $24 |
| BioCryst US Sales Co., LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: DUPIXENT, AIRSUPRA, Xembify, HYQVIA, OCTAGAM IMMUNE GLOBULIN (HUMAN), TAKHZYRO, ORLADEYO, FASENRA.
Industry payments across TX — which companies pay providers there.
